Answers are grounded in this paper and cite their sources.
Aptamers are known to inhibit protein aggregation, and understanding the mechanism of how they modulate aggregation pathway and morphology is essential for developing aptamer-based strategies for aggregation associated diseases. Here, we characterized the aggregation behavior of the model protein human serum albumin (HSA) under two distinct destabilizing conditions and examined how a DNA aptamer modulates these aggregation pathways using a combination of microscopic, spectroscopic, computational and calorimetric approaches. At 65 °C, HSA formed fibrillar aggregates displaying both linear and branched morphologies. In contrast, reduction of its disulfide bonds produced amorphous aggregates in the presence of dithiothreitol (DTT), whereas Tris(2-carboxyethyl)phosphine (TCEP) resulted in a mixture of amorphous and β-sheet-rich aggregates. The H8-aptamer binds to HSA by wrapping around the protein and altered its aggregation behavior depending on the experimental conditions. At 65 °C, the aptamer binding suppressed fibril formation of HSA. Under reducing conditions, however, the H8-aptamer did not prevent aggregation but instead altered the aggregate morphology. In the presence of DTT, the aggregates exhibited linear and branched morphologies, whereas TCEP resulted in the formation of spherical aggregates. Molecular dynamics simulations further supported these findings by revealing domain-specific alterations in HSA dynamics that depended on the nature of the destabilizing condition. These results highlight the importance of designing aptamers that can enhance the stability of multiple domains and inhibit the aggregation of multidomain proteins.
No takes yet. Share an insight, caveat, or question.
Pasangha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: